RENVELA

Drug SANOFI-AVENTIS U.S. LLC
Total Payments
$158,080
Transactions
2,288
Doctors
1,251
Companies
2

Payment Trends by Year

Year Amount Transactions Doctors
2019 $25,664 8 1
2018 $266.62 14 14
2017 $132,149 2,266 1,246

Payments by Nature

Nature of Payment Amount Transactions Share
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $79,829 10 50.5%
Food and Beverage $40,183 2,244 25.4%
Travel and Lodging $27,238 24 17.2%
Unspecified $5,498 7 3.5%
Consulting Fee $5,332 3 3.4%

Payments by Type

General
$152,582
2,281 transactions
Research
$5,498
7 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease GENZYME CORPORATION $5,498 7

Top Doctors Receiving Payments for RENVELA — Page 49

Doctor Specialty Location Total Records
, M.D Nephrology Columbia, SC $11.72 1
, M.D Nephrology Park Ridge, IL $11.71 1
, MD Nephrology Fort Dodge, IA $11.65 1
, M.D Nephrology Phoenix, AZ $11.56 1
, M.D Nephrology Paterson, NJ $11.50 1
, MD Nephrology Oklahoma City, OK $11.49 1
, M.D Specialist Bayamon, PR $11.46 1
, M.D Specialist Savannah, GA $11.45 1
, M.D Nephrology Chicago, IL $11.45 1
, M.D Nephrology Merrillville, IN $11.44 1
, M.D Nephrology Thomasville, GA $11.44 1
, MD Nephrology Merrillville, IN $11.44 1
, M.D Nephrology Alexandria, LA $11.42 1
, D.O Nephrology Flagstaff, AZ $11.37 1
, M.D Nephrology Phoenix, AZ $11.37 1
, M.D Internal Medicine Birmingham, AL $11.37 1
, D.O Nephrology Indianapolis, IN $11.36 1
, MD Nephrology Indianapolis, IN $11.36 1
, MD Internal Medicine Wichita, KS $11.34 1
, M.D Nephrology Wichita, KS $11.34 1
, MD Internal Medicine Wayne, NJ $11.33 1
, MD Nephrology Jacksonville, FL $11.28 1
, MD Nephrology Sioux Falls, SD $11.26 1
, M.D Internal Medicine Nashville, TN $11.25 1
, M.D Nephrology San Antonio, TX $11.24 1

About RENVELA

RENVELA is a drug associated with $158,080 in payments to 1,251 healthcare providers, recorded across 2,288 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI-AVENTIS U.S. LLC.

Payment data is available from 2017 to 2019. In 2019, $25,664 was paid across 8 transactions to 1 doctors.

The most common payment nature for RENVELA is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($79,829, 50.5% of total).

RENVELA is associated with 1 research study, including "Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease" ($5,498).